Abbott Laboratories Comprehensive Income 2010-2024 | ABT
Abbott Laboratories comprehensive income from 2010 to 2024. Comprehensive income can be defined as the change in net assets of a business enterprise during a period from transactions and other events and circumstances from nonowner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.
- Abbott Laboratories comprehensive income for the quarter ending September 30, 2024 was $-7.804B, a 7.97% decline year-over-year.
- Abbott Laboratories comprehensive income for 2023 was $-7.839B, a 2.63% decline from 2022.
- Abbott Laboratories comprehensive income for 2022 was $-8.051B, a 3.86% decline from 2021.
- Abbott Laboratories comprehensive income for 2021 was $-8.374B, a 6.39% decline from 2020.
| Abbott Laboratories Annual Comprehensive Income (Millions of US $) |
|
|---|---|
| 2023 | $-7,839 |
| 2022 | $-8,051 |
| 2021 | $-8,374 |
| 2020 | $-8,946 |
| 2019 | $-8,465 |
| 2018 | $-7,586 |
| 2017 | $-6,062 |
| 2016 | $-7,263 |
| 2015 | $-6,658 |
| 2014 | $-5,053 |
| 2013 | $-2,012 |
| 2012 | $-3,594 |
| 2011 | $-2,597 |
| 2010 | $-1,367 |
| 2009 | $854 |
| Abbott Laboratories Quarterly Comprehensive Income (Millions of US $) |
|
|---|---|
| 2024-09-30 | $-7,804 |
| 2024-06-30 | $-8,135 |
| 2024-03-31 | $-8,166 |
| 2023-12-31 | $-7,839 |
| 2023-09-30 | $-8,480 |
| 2023-06-30 | $-8,071 |
| 2023-03-31 | $-8,039 |
| 2022-12-31 | $-8,051 |
| 2022-09-30 | $-9,445 |
| 2022-06-30 | $-8,706 |
| 2022-03-31 | $-8,474 |
| 2021-12-31 | $-8,374 |
| 2021-09-30 | $-9,240 |
| 2021-06-30 | $-9,066 |
| 2021-03-31 | $-9,285 |
| 2020-12-31 | $-8,946 |
| 2020-09-30 | $-9,044 |
| 2020-06-30 | $-9,080 |
| 2020-03-31 | $-9,386 |
| 2019-12-31 | $-8,465 |
| 2019-09-30 | $-7,763 |
| 2019-06-30 | $-7,365 |
| 2019-03-31 | $-7,470 |
| 2018-12-31 | $-7,586 |
| 2018-09-30 | $-7,009 |
| 2018-06-30 | $-6,913 |
| 2018-03-31 | $-5,733 |
| 2017-12-31 | $-6,062 |
| 2017-09-30 | $-6,116 |
| 2017-06-30 | $-6,250 |
| 2017-03-31 | $-6,532 |
| 2016-12-31 | $-7,263 |
| 2016-09-30 | $-6,533 |
| 2016-06-30 | $-7,223 |
| 2016-03-31 | $-6,851 |
| 2015-12-31 | $-6,658 |
| 2015-09-30 | $-7,211 |
| 2015-06-30 | $-5,004 |
| 2015-03-31 | $-5,607 |
| 2014-12-31 | $-5,053 |
| 2014-09-30 | $-2,975 |
| 2014-06-30 | $-1,952 |
| 2014-03-31 | $-1,934 |
| 2013-12-31 | $-2,012 |
| 2013-09-30 | $-2,957 |
| 2013-06-30 | $-3,226 |
| 2013-03-31 | $-2,895 |
| 2012-12-31 | $-3,594 |
| 2012-09-30 | $-2,756 |
| 2012-06-30 | $-3,544 |
| 2012-03-31 | $-1,941 |
| 2011-12-31 | $-2,597 |
| 2011-09-30 | $-860 |
| 2011-06-30 | $578 |
| 2011-03-31 | $182 |
| 2010-12-31 | $-1,367 |
| 2010-09-30 | $-1,483 |
| 2010-06-30 | $-2,629 |
| 2010-03-31 | $-976 |
| 2009-12-31 | $854 |
| 2009-09-30 | $499 |
| 2009-06-30 | $-7 |
| 2009-03-31 | $-1,195 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $194.797B | $40.109B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boston Scientific (BSX) | United States | $139.837B | 40.20 |
| Stryker (SYK) | United States | $139.395B | 31.41 |
| EssilorLuxottica (ESLOY) | France | $110.104B | 0.00 |
| Medtronic (MDT) | Ireland | $103.429B | 15.36 |
| Lonza Group Ag (LZAGY) | Switzerland | $43.664B | 0.00 |
| Haleon (HLN) | United Kingdom | $41.193B | 26.76 |
| GE HealthCare Technologies (GEHC) | United States | $38.725B | 20.09 |
| ResMed (RMD) | United States | $34.324B | 28.21 |
| Terumo (TRUMY) | Japan | $28.025B | 39.58 |
| Koninklijke Philips (PHG) | Netherlands | $24.269B | 18.58 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.811B | 13.25 |
| Insulet (PODD) | United States | $19.068B | 75.93 |
| Baxter (BAX) | United States | $15.022B | 9.77 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.471B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $9.568B | 32.52 |
| BellRing Brands (BRBR) | United States | $9.145B | 36.79 |
| Demant (WILYY) | Denmark | $8.596B | 0.00 |
| Lantheus Holdings (LNTH) | United States | $6.666B | 15.49 |
| Haemonetics (HAE) | United States | $3.851B | 18.79 |
| ICU Medical (ICUI) | United States | $3.779B | 35.98 |
| Prestige Consumer Healthcare (PBH) | United States | $3.656B | 18.18 |
| Perrigo (PRGO) | Ireland | $3.326B | 9.79 |
| Envista Holdings (NVST) | United States | $3.198B | 23.82 |
| QuidelOrtho (QDEL) | United States | $3.077B | 19.81 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.010B | 0.00 |
| Neogen (NEOG) | United States | $2.678B | 30.90 |
| GN Store Nord (GNNDY) | Denmark | $2.593B | 16.63 |
| LeMaitre Vascular (LMAT) | United States | $2.104B | 51.14 |
| Green Thumb Industries (GTBIF) | United States | $1.564B | 27.37 |
| AtriCure (ATRC) | United States | $1.531B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.364B | 9.75 |
| InMode (INMD) | Israel | $1.335B | 8.03 |
| BioLife Solutions (BLFS) | United States | $1.234B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.225B | 0.00 |
| Owens & Minor (OMI) | United States | $1.071B | 8.37 |
| Curaleaf Holdings (CURLF) | Canada | $0.942B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.812B | 14.32 |
| CeriBell (CBLL) | United States | $0.750B | 0.00 |
| Evolus (EOLS) | United States | $0.633B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.600B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.551B | 24.31 |
| Surmodics (SRDX) | United States | $0.549B | 0.00 |
| Omeros (OMER) | United States | $0.512B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.459B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.423B | 0.00 |
| ZimVie (ZIMV) | United States | $0.372B | 31.37 |
| Valneva SE (VALN) | France | $0.369B | 0.00 |
| Quanterix (QTRX) | United States | $0.363B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.310B | 29.44 |
| Biote (BTMD) | United States | $0.307B | 6.73 |
| Cerus (CERS) | United States | $0.293B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.282B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.270B | 18.10 |
| Canopy Growth (CGC) | Canada | $0.267B | 0.00 |
| High Tide (HITI) | Canada | $0.250B | 103.00 |
| Zynex (ZYXI) | United States | $0.249B | 52.20 |
| Aurora Cannabis (ACB) | Canada | $0.227B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.224B | 3.15 |
| Utah Medical Products (UTMD) | United States | $0.207B | 14.26 |
| MacroGenics (MGNX) | United States | $0.200B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.198B | 0.00 |
| Brainsway (BWAY) | Israel | $0.177B | 94.00 |
| TerrAscend (TSNDF) | Canada | $0.164B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.157B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.137B | 17.21 |
| Quipt Home Medical (QIPT) | United States | $0.129B | 0.00 |
| Jin Medical (ZJYL) | China | $0.126B | 0.00 |
| Veru (VERU) | United States | $0.114B | 0.00 |
| Fonar (FONR) | United States | $0.096B | 10.88 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.096B | 0.00 |
| InterCure (INCR) | Israel | $0.076B | 0.00 |
| INLIF (INLF) | $0.068B | 0.00 | |
| Rockwell Medical (RMTI) | United States | $0.067B | 34.67 |
| Apyx Medical (APYX) | United States | $0.060B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.059B | 0.00 |
| Exagen (XGN) | United States | $0.056B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.052B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.051B | 0.00 |
| ImmuCell (ICCC) | United States | $0.046B | 0.00 |
| Modular Medical (MODD) | United States | $0.046B | 0.00 |
| Safety Shot (SHOT) | United States | $0.037B | 0.00 |
| Nephros (NEPH) | United States | $0.016B | 0.00 |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.012B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.010B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.008B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.008B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| Agape ATP (ATPC) | $0.005B | 0.00 | |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.002B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.001B | 0.00 |
| United-Guardian (UG) | United States | $0.000B | 13.30 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.000B | 0.00 |